Experimental Neurotherapeutics: Surfing the Tidal Wave of New Opportunities
Corresponding Author
Lauren B. Reoma MD
Clinical Trials Unit, Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA
Address correspondence to Dr Reoma, Clinical Trials Unit, Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, Bethesda, MD 20814, USA. E-mail: [email protected]
Search for more papers by this authorAnia Busza MD, PhD
University of Rochester School of Medicine and Dentistry, Department of Medicine, Rochester Regional Health; Department of Medicine, Division of Allergy, Immunology, and Rheumatology, Rochester, NY, USA
Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
Search for more papers by this authorM. Maral Mouradian MD
RWJMS Institute for Neurological Therapeutics and Department of Neurology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA
Search for more papers by this authorPetra Kaufmann MD
Affinia Therapeutics, Bannockburn, MA, USA
University of Rochester, Rochester, NY, USA
Search for more papers by this authorErika F. Augustine MD, MS
Kennedy Krieger Institute, Baltimore, MD, USA
Search for more papers by this authorSamuel Frank MD
Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Search for more papers by this authorThomas P. Sutula MD, PhD
Department of Neurology, University of Wisconsin, Madison, WI, USA
Search for more papers by this authorAndrew J. Cole MD
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Search for more papers by this authorHeather D. Fitter MD
Division of Neurology II, Office of Neuroscience, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
Search for more papers by this authorWilliam Meurer MD, MS
Department of Emergency Medicine, University of Michigan, Ann Arbor, MI, USA
Michigan Center for Integrative Research in Critical Care, Ann Arbor, MI, USA
Department of Neurology, University of Michigan, Ann Arbor, MI, USA
Stroke Program, University of Michigan, Ann Arbor, MI, USA
Berry Consultants, Austin, TX, USA
Search for more papers by this authorAvindra Nath MD
Clinical Trials Unit, Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA
Search for more papers by this authorRobert C. Griggs MD
University of Rochester School of Medicine and Dentistry, Department of Medicine, Rochester Regional Health; Department of Medicine, Division of Allergy, Immunology, and Rheumatology, Rochester, NY, USA
Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
Search for more papers by this authorCorresponding Author
Lauren B. Reoma MD
Clinical Trials Unit, Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA
Address correspondence to Dr Reoma, Clinical Trials Unit, Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, Bethesda, MD 20814, USA. E-mail: [email protected]
Search for more papers by this authorAnia Busza MD, PhD
University of Rochester School of Medicine and Dentistry, Department of Medicine, Rochester Regional Health; Department of Medicine, Division of Allergy, Immunology, and Rheumatology, Rochester, NY, USA
Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
Search for more papers by this authorM. Maral Mouradian MD
RWJMS Institute for Neurological Therapeutics and Department of Neurology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA
Search for more papers by this authorPetra Kaufmann MD
Affinia Therapeutics, Bannockburn, MA, USA
University of Rochester, Rochester, NY, USA
Search for more papers by this authorErika F. Augustine MD, MS
Kennedy Krieger Institute, Baltimore, MD, USA
Search for more papers by this authorSamuel Frank MD
Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Search for more papers by this authorThomas P. Sutula MD, PhD
Department of Neurology, University of Wisconsin, Madison, WI, USA
Search for more papers by this authorAndrew J. Cole MD
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Search for more papers by this authorHeather D. Fitter MD
Division of Neurology II, Office of Neuroscience, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
Search for more papers by this authorWilliam Meurer MD, MS
Department of Emergency Medicine, University of Michigan, Ann Arbor, MI, USA
Michigan Center for Integrative Research in Critical Care, Ann Arbor, MI, USA
Department of Neurology, University of Michigan, Ann Arbor, MI, USA
Stroke Program, University of Michigan, Ann Arbor, MI, USA
Berry Consultants, Austin, TX, USA
Search for more papers by this authorAvindra Nath MD
Clinical Trials Unit, Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA
Search for more papers by this authorRobert C. Griggs MD
University of Rochester School of Medicine and Dentistry, Department of Medicine, Rochester Regional Health; Department of Medicine, Division of Allergy, Immunology, and Rheumatology, Rochester, NY, USA
Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
Search for more papers by this authorAbstract
The subspecialty of experimental neurotherapeutics trains neurologists in discovering and developing new treatments for neurologic diseases. Based on development of exciting new treatments for genetic and inflammatory diseases, we predict that there will be many other breakthroughs. The job market has expanded rapidly in academia, the pharmaceutical industry, government, and not-for-profit sectors; many new opportunities can be anticipated. The burgeoning opportunities in the field mandate that training address the challenges of overcoming obstacles in therapeutic discovery, implementation science, and development of affordable and equitably available treatments. ANN NEUROL 2023;93:427–430
Potential Conflicts of Interest
M.M.M. is the Editor-in-Chief of Neurotherapeutics. T.P.S. is the President of ASENT. A.J.C. is the incoming President of ASENT. The remaining authors have nothing to report.
References
- 1Fu KA, Saver JL, Perlman S. Emerging subspecialties in neurology: a career as a clinical trialist in neurology. Neurology 2022; 98: 940–944.
- 2Statland JM, Griggs RC, Augustine EF. Emerging subspecialties in neurology: fellowship in experimental therapeutics of neurologic disease. Neurology 2012; 79: e106–e108.
- 3Cedarbaum JM, Stephenson D, Rudick R, et al. Commonalities and challenges in the development of clinical trial measures in neurology. Neurotherapeutics 2015; 12: 151–169.
- 4Ness EA, Royce C. Clinical trials and the role of the oncology clinical trials nurse. Nurs Clin North Am 2017; 52: 133–148.
- 5Collins FS, Schwetz TA, Tabak LA, Lander ES. ARPA-H: accelerating biomedical breakthroughs. Science 2021; 373: 165–167.
- 6Dorsey ER, Kluger B, Lipset CH. The new Normal in clinical trials: decentralized studies. Ann Neurol 2020; 88: 863–866.
- 7Wouters OJ, McKee M, Luyten J. Estimated Research and Development investment needed to bring a new medicine to market, 2009-2018. JAMA 2020; 323: 844–853.
- 8Moses H 3rd, Dorsey ER, Matheson DH, Thier SO. Financial anatomy of biomedical research. JAMA 2005; 294: 1333–1342.
- 9Dorsey ER, de Roulet J, Thompson JP, et al. Funding of US biomedical research, 2003-2008. JAMA 2010; 303: 137–143.
- 10Hopewell S, Clarke M, Stewart L, Tierney J. Time to publication for results of clinical trials. Cochrane Database Syst Rev 2007; 2007: Mr000011.
- 11Kaufmann P, Annis C, Griggs RC. The authorship lottery: an impediment to research collaboration? Ann Neurol 2010; 68: 782–786.
- 12Feyman Y, Provenzano F, David FS. Disparities in clinical trial access across US urban areas. JAMA Netw Open 2020; 3:e200172.
- 13Hall DA, Ramos AR, Gelfand JM, et al. The state of clinical research in neurology. Neurology 2018; 90: e1347–e1354.
Citing Literature
